46 related articles for article (PubMed ID: 38451273)
1. A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04).
Salani R; McCormack M; Kim YM; Ghamande S; Hall SL; Lorusso D; Barraclough L; Gilbert L; Guzman Ramirez A; Lu CH; Sabatier R; Colombo N; Hu Y; Krishnan V; Molinero L; Feng Y; Kim N; Castro M; Lin YG; Monk BJ
Int J Gynecol Cancer; 2024 Jun; ():. PubMed ID: 38858106
[TBL] [Abstract][Full Text] [Related]
2. IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma.
Badhrinarayanan S; Cotter C; Zhu H; Lin YC; Kudo M; Li D
Future Oncol; 2024 Jun; ():1-9. PubMed ID: 38861301
[TBL] [Abstract][Full Text] [Related]
3. Killing a fly with a sledgehammer: Atezolizumab exposure in real-world lung cancer patients.
Marolleau S; Mogenet A; Boeri C; Hamimed M; Ciccolini J; Greillier L
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1795-1803. PubMed ID: 38011601
[TBL] [Abstract][Full Text] [Related]
4. Anti-TIGIT therapies for solid tumors: a systematic review.
Rousseau A; Parisi C; Barlesi F
ESMO Open; 2023 Apr; 8(2):101184. PubMed ID: 36933320
[TBL] [Abstract][Full Text] [Related]
5. Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno.
Brazel D; Ou SI; Nagasaka M
Lung Cancer (Auckl); 2023; 14():1-9. PubMed ID: 36636263
[TBL] [Abstract][Full Text] [Related]
6. Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors.
Shemesh CS; Wang Y; An A; Ding H; Chan P; Liu Q; Chen YW; Wu B; Wu Q; Wang X
Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38451273
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
Yamamoto N; Koyama T; Sato J; Yoshida T; Sudo K; Iwasa S; Kondo S; Yonemori K; Kawasaki A; Satake K; Shibata S; Shimizu T
Cancer Chemother Pharmacol; 2024 Jan; ():. PubMed ID: 38206370
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
Garralda E; Oh DY; Italiano A; Bedard PL; Delord JP; Calvo E; LoRusso P; Wainberg Z; Cervantes A; Rodriguez-Vida A; Shemesh CS; Sane R; Mendus D; Ding H; Hendricks R; Meng R; Cho BC; Kim TW; Wu B
J Clin Pharmacol; 2024 May; 64(5):544-554. PubMed ID: 38105505
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
Roussot N; Fumet JD; Limagne E; Thibaudin M; Hervieu A; Hennequin A; Zanetta S; Dalens L; Fourrier T; Galland L; Jacob P; Bertaut A; Rederstorff E; Chevalier C; Ghirardi S; Gilbert E; Khoukaz A; Martin E; Nicolet C; Quivrin M; Thibouw D; Vulquin N; Truc G; Rouffiac M; Ghiringhelli F; Mirjolet C
BMC Cancer; 2023 Nov; 23(1):1080. PubMed ID: 37946136
[TBL] [Abstract][Full Text] [Related]
10. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
Kim TW; Bedard PL; LoRusso P; Gordon MS; Bendell J; Oh DY; Ahn MJ; Garralda E; D'Angelo SP; Desai J; Hodi FS; Wainberg Z; Delord JP; Cassier PA; Cervantes A; Gil-Martin M; Wu B; Patil NS; Jin Y; Hoang T; Mendus D; Wen X; Meng R; Cho BC
JAMA Oncol; 2023 Nov; 9(11):1574-1582. PubMed ID: 37768658
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review.
Shang J; Huang L; Huang J; Ren X; Liu Y; Feng Y
Front Immunol; 2022; 13():871372. PubMed ID: 35983041
[TBL] [Abstract][Full Text] [Related]
12. The top 5 causes of death in China from 2000 to 2017.
Zou H; Li Z; Tian X; Ren Y
Sci Rep; 2022 May; 12(1):8119. PubMed ID: 35581260
[TBL] [Abstract][Full Text] [Related]
13. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
